s6y

BioLineRx Ltd.

Nasdaq
BLRX
CIK
1498403
Industry
Pharmaceutical Preparations
Incorporated in
Israel
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer

Key figures

Fiscal year to Dec 2025 Dec 2024 Dec 2023 Dec 2022 Dec 2021
Revenue $1.18M$28.9M$4.80M––
Operating income −$10.3M−$20.4M−$49.7M−$29.2M−$24.8M
Net income −$2.03M−$9.22M−$60.6M−$25.0M−$27.1M
Diluted EPS $0.00−$0.01−$0.06−$0.03−$0.04
Cash from operations −$8.07M−$43.9M−$22.6M−$26.2M−$23.6M
Total assets $40.9M$38.9M$63.9M$76.4M$81.4M
Shareholders’ equity $18.2M$13.5M$13.2M$50.8M$68.1M

From the company’s annual reports to the SEC. Each year links to its report.

Financials 25

  1. 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2025
  2. 20-F Annual report (foreign issuer) for period ending Dec 31, 2025
  3. 20-F Annual report (foreign issuer) for period ending Dec 31, 2024
  4. 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2023
  5. 20-F Annual report (foreign issuer) for period ending Dec 31, 2023
  6. 20-F Annual report (foreign issuer) for period ending Dec 31, 2022
  7. 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2021
  8. 20-F Annual report (foreign issuer) for period ending Dec 31, 2021
  9. 20-F Annual report (foreign issuer) for period ending Dec 31, 2020
  10. 20-F Annual report (foreign issuer) for period ending Dec 31, 2019

All 25 financials filings

News 402

  1. 6-K Current report (foreign issuer)
  2. 6-K Current report (foreign issuer)
  3. 6-K Current report (foreign issuer)
  4. 6-K Current report (foreign issuer)
  5. 6-K Current report (foreign issuer)
  6. 6-K Current report (foreign issuer)
  7. 6-K Current report (foreign issuer)
  8. 6-K Current report (foreign issuer)
  9. 6-K Current report (foreign issuer)
  10. 6-K Current report (foreign issuer)

All 402 news filings

Ownership 66

  1. SCHEDULE 13G Major shareholder report (passive investor)
  2. 3 Initial statement of insider ownership
  3. 3 Initial statement of insider ownership
  4. 3 Initial statement of insider ownership
  5. 3 Initial statement of insider ownership
  6. 3 Initial statement of insider ownership
  7. 3 Initial statement of insider ownership
  8. 3 Initial statement of insider ownership
  9. 3 Initial statement of insider ownership
  10. 3 Initial statement of insider ownership

All 66 ownership filings

Prospectus 52

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 52 prospectus filings

Other 75

  1. EFFECT Notice of Effectiveness
  2. F-1 Registration statement for securities of certain foreign private issuers
  3. D Exempt (Private) Offering
  4. EFFECT Notice of Effectiveness
  5. F-3 Registration statement for specified transactions by certain foreign private issuers
  6. CT ORDER Order Granting Confidential Treatment
  7. EFFECT Notice of Effectiveness
  8. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  9. EFFECT Notice of Effectiveness
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 75 other filings

Others in Pharmaceutical Preparations

Every company in this industry